About Event

Calling all CAR and TCR Drug Developers – Welcome to the CAR-TCR Summit

 

With the 4th CAR-T gaining long-awaited approval, Bristol-Myers Squibb have stepped onto the commercial stage, and the CAR-TCR field continues to boom with excitement as the competition heats up.

The current approved therapies have encountered significant difficulties in the commercial market. Cell Therapies come with a high price tag, little long-term efficacy data, and expensive manufacturing processes. Now, your community must gather to:

Achieve consistency in manufacturing, focusing on automation, allogeneic platforms,  scalability, and engineering techniques
Demonstrate durable response with enhanced construct design, optimized trial design, and long-term follow-up data
Overcome solid tumor hurdles with combination strategy, specialized clinical delivery, and next-generation engineering strategies

 

These challenges require ground-breaking work, from discovery through to commercialization. Join the CAR-TCR Summit to learn from the key opinion leaders, and international innovators of the CAR-TCR community.

Breakdown of the 2021 Agenda

Pre-Summit Workshops & Bootcamps

New this year: Regulations Bootcamp

Accelerate regulatory submissions with end-to-end  oversight of the processes and requirements for advanced therapies. Learn from seasoned experts, sharing their experience from IND submissions to post-BLA approval, and plan for success.

 

12 discussion-based workshops

Arm your team with the opportunity to collaborate in an intimate environment with fellow CAR-TCR drug developers who are actively working on the same challenges you may be facing.

This interactive opportunity is the perfect environment to ask your specific questions with topic experts and gain actionable insights on key challenges including:

  • Investigating solid tumor biology to inform therapeutic design
  • Defining the pharmacology of CAR-T and TCR-T to optimize clinical outcomes & design
  • Scaling manufacturing for faster, cheaper, and consistent production

 

CAR-TCR 101

If you are new to your role in the CAR-TCR field or an emerging biotech in the space, join this one-day intensive learning environment to establish core skills and understanding from R&D through to manufacturing considerations to support early stage clinical trials.

2 Summit Days: 7 Tracks

 

New this year: Early Phase Development Track

With more than 80% of companies between phase 1 or 2 trials, we have created a dedicated forum to share learnings and insights to advance streamlined workflows, informed by our industry 'brain trust' of seasoned experts.

Providing your team with the full end-to-end drug development landscape, the two main summit days are divided across 7 comprehensive tracks of content:

  1. Discovery
  2. Translation
  3. Clinical Management
  4. Early Phase Development
  5. Manufacturing
  6. Logistics
  7. Market Access

Bring your team to divide and conquer, ensuring your whole company can benefit from the full range of world-class expertise being showcased.

Post-Summit Focus Day

 

New this year: Cell Characterization Focus

Highlighting the emerging areas of interest in the field, this 2 tracked focus day agenda will provide a dedicated opportunity to  explore the emerging opportunities in the field.

 

  1. Cell Characterization

Hear how experts are advancing pre-clinical assay development for in-depth analysis of mechanism of action and IND excellence. Advance CMC and analytical workstreams with leading industry experts, and explore cutting-edge tech platforms with our world-class partners.

 

  1. CAR-TCR Beyond Oncology

Review preclinical and clinical development of CAR-T therapies in HIV, autoimmunity, lupus, transplantation and cardiovascular disease to understand the full potential CAR-T therapies can have to engineer a disease-free world.

Introducing Our Scientific Advisory Board

Picture6

Adrian Bot

Global Head Translational Medicine

Kite: A Gilead Company

Annotation 2021-02-10 150954

Adrienne Farid

CDO

Century Therapeutics

Picture10

Axel Hoos

SVP, R&D Governance Chair & Therapeutic Area Head Oncology

GSK

Annotation 2021-02-10 151111

Barbra Sasu

CSO

Allogene

Annotation 2021-02-10 151135

Bruce Levine

Barbara and Edward Netter Professor in Cancer Gene Therapy

Perelman School of Medicine

Annotation 2021-02-10 151811

Bob Valamehr

CDO

Fate Therapeutics

Picture5

Dolores Schendel

CEO & CSO

Medigene

Annotation 2021-02-10 151945

Gregory Fiore

CEO

Exacis

Picture4

Margo Roberts

krishnan

Krishnan Viswanadhan

SVP, Global Cell Therapy Franchise Lead

Bristol Myers Squibb

“To support the CAR-TCR Summit in its role at the forefront of the industry, providing a progressive end-to-end forum, we have shared our expertise to shape the agenda into a truly don’t miss’ event”

CAR-TCR Scientific Advisory Board

"It is a must-visit forum for anyone directly involved in the field. Due to its thorough agenda, covering research to regulatory with a focus on industry’s perspective, it complements the experience that can be gained through any other strictly scientific meeting” ★★★★★

gilead sciences

"The summit was an incredible conflagration of the top companies and experts in the field of T-cell therapy" ★★★★★

University of New Haven

Connect with us on Social Media